Tackling the blind spot of poor-quality medicines in Universal Health Coverage

References

• WHO. Universal health coverage (UHC). 2020. [cited 2020 Jan 24]. Available from: https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc).
   Google Scholar
• Hogan DR, Stevens GA, Hosseinpoor AR, Boerma T. Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services. Lancet Glob Health. 2018;6(2):e152–e168.
   PubMed Web of Science ®Google Scholar
• United Nations Statistics Division. Global indicator framework for the Sustainable Development Goals and targets of the 2030 Agenda for Sustainable Development; 2020. p. 21. Report No.: A/RES/71/313. Available from: https://unstats.un.org/sdgs/indicators/Global%20Indicator%20Framework%20after%202019%20refinement_Eng.pdf
   Google Scholar
• Management Sciences for Health. MDS-3: Managing access to medicines and health technologies. 2012 [cited 2020 Feb 4]. Available from: https://www.msh.org/sites/default/files/mds3-jan2014.pdf
   Google Scholar
• WHO. Local production for access to medical products: developing a framework to improve public health. Genève (Suisse): OMS, World Health Organization; 2012.
   Google Scholar
• Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403–476.
   PubMedGoogle Scholar
• WHO. WHO Global Surveillance and Moonitoring System for Substandard and Falsified Medical Products. 2017. [cited 2019 Dec 25]. Available from: https://apps.who.int/iris/bitstream/handle/10665/326708/9789241513425-eng.pdf?ua=1
   Google Scholar
• Sprenger M. Global Action Plan on Antimicrobial Resistance: DRIVE AB Presentation - Setting the Scene. [cited 2020 Feb 4]. Available from: http://drive-ab.eu/wp-content/uploads/2017/09/Marc-Sprenger_Global-AMR-PDF-Protected.pdf.
   Google Scholar
• Weinstein ZB, Zaman MH. Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs. Antimicrob Agents Chemother. 2018;63(1):e01243–e01218. Published 2018 Dec 21. https://doi.org/10.1128/AAC.01243-18.
   PubMed Web of Science ®Google Scholar
• Nwokike J, Clark A, Nguyen PP. Medicines quality assurance to fight antimicrobial resistance. Bull World Health Org. 2018;96(2):135–137.
   PubMed Web of Science ®Google Scholar
• Mackey TK, Liang BA, York P, Kubic T. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. Am J Trop Med Hyg. 2015;92(6 Suppl):59–67.
   PubMed Web of Science ®Google Scholar
• Hall A, Antonopoulos G. Fake Meds Online: The Internet and the Transnational Market in Illicit Pharmaceuticals: Palgrave Macmillan Ltd; 2016. [cited 2020 Feb 4]. Available from: https://research.tees.ac.uk/en/publications/fake-meds-online-the-internet-and-the-transnational-market-in-ill-3.
   Google Scholar
• Jack A. Can anyone stop the illegal sale of medicines online? BMJ. 2016;352:i1317.
   PubMedGoogle Scholar
• Kaiser Health News. Purveyors of Black-Market Pharmaceuticals Target Immigrants. US News & World Report. [cited 2020 Feb 4]. Available from: https://www.usnews.com/news/healthiest-communities/articles/2019-09-16/purveyors-of-black-market-pharmaceuticals-target-immigrants.
   Google Scholar
• WHO. A study on the public health and socioeconomic impact of substandard and falsified medical products. WHO. [cited 2020 Feb 4]. Available from: http://www.who.int/medicines/regulation/ssffc/publications/se-study-sf/en/.
   Google Scholar
• Ozawa S, Pribluda V, Yemeke TT, Higgins CR, Hajjou M, Evans III L, et al. Integrating medicines quality assurance into Universal Healthcare programming. USP PQM; 2019. [cited 2020 Feb 4]. Available from: https://www.usp-pqm.org/sites/default/files/field/image/pqm-uhc-white-paper.pdf.
   Google Scholar
• Renschler JP, Walters KM, Newton PN, Laxminarayan R. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa. Am J Trop Med Hyg. 2015;92(6 Suppl):119–126.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1(4):e181662.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences E and Medicine. Crossing the Global Quality Chasm: Improving Health Care Worldwide. Washington, DC: The National Academies Press; 2018. Available from: https://www.nap.edu/catalog/25152/crossing-the-global-quality-chasm-improving-health-care-worldwide.
   Google Scholar
• Beargie SM, Higgins CR, Evans DR, Laing SK, Erim D, Ozawa S. The economic impact of substandard and falsified antimalarial medications in Nigeria. PLoS One. 2019;14(8):e0217910.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Haynie DG, Bessias S, Laing SK, Ngamasana EL, Yemeke TT, et al. Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2019;100(5):1149–1157.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Evans DR, Higgins CR, Laing SK, Awor P. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study. Malar J. 2019;18(1):5–5.
   PubMedGoogle Scholar
• Ledy NM. DRC: $ 5.9 billion budget for 2019. Available from: https://www.kapitalafrik.com/2018/10/12/drc-5-9-billion-budget-for-2019/. [cited 2020 Apr 22].
   Google Scholar
• Emmanuel KI. The Access to health care in the Democratic Republic of Congo: Major challenge for the poor. J Nurs Palliat Care Serv (NPCS). 2016;1:103.
   Google Scholar
• Federal Ministry of Health. Nigeria Health Facility Registry. 2019 [cited 2020 Feb 4]. Available from: https://hfr.health.gov.ng/statistics/tables.
   Google Scholar
• Ministry of Health, Republic of Uganda. Hospitals | Ministry of Health [Internet]. [cited 2020 Feb 4]. Available from: https://health.go.ug/hospitals.
   Google Scholar
• Bertone MP, Lurton G, Mutombo PB. Investigating the remuneration of health workers in the DR Congo: implications for the health workforce and the health system in a fragile setting. Health Policy Plan. 2016;31(9):1143–1151.
   PubMed Web of Science ®Google Scholar
• Obua TO, Adome RO, Kutyabami P, Kitutu FE, Kamba PF. Factors associated with occupancy of pharmacist positions in public sector hospitals in Uganda: a cross-sectional study. Hum Resour Health. 2017;15(1):1–1.
   PubMedGoogle Scholar
• Ubaka CM, Ochie UM, Adibe MO. Student pharmacists’ career choices: a survey of three Nigerian schools of pharmacy. Pharm Pract (Granada). 2013;11(3):149–155.
   PubMedGoogle Scholar
• Ministry of Finance, Planning and Economic Development. National-Budget-Framework-Paper-FY-2019-20.pdf. 2018 [cited 2020 Feb 4]. Available from: http://csbag.org/wp-content/uploads/2019/01/National-Budget-Framework-Paper-FY-2019-20.pdf.
   Google Scholar
• WHO. WHO | Guidelines for the development of measures to combat counterfeit medicines: WHO; 1999. [cited 2020 Feb 4]. Available from: http://www.who.int/medicines/publications/counterfeitguidelines/en/.
   Google Scholar
• Institute of Medicine. Countering the Problem of Falsified and Substandard Drugs. Washington, DC: The National Academies Press; 2013. Available from: https://www.nap.edu/catalog/18272/countering-the-problem-of-falsified-and-substandard-drugs.
   Google Scholar
• Ubajaka C, Obi-Okaro A, Emelumadu O, Azumarah M, Ukegbu A, Ilikannu S. Factors Associated with Drug Counterfeit in Nigeria: A Twelve Year Review. BJMMR. 2016;12(4):1–8.
   Google Scholar
• Amadi C, Tsui EK. How the quality of essential medicines is perceived and maintained through the pharmaceutical supply chain: A perspective from stakeholders in Nigeria. Res Soc Adm Pharm. 2019;15(11):1344–1357.
   PubMed Web of Science ®Google Scholar
• Glass B. Counterfeit drugs and medical devices in developing countries. Res Rep Trop Med. 2014;11.
   Google Scholar
• Christian L, Collins L, Kiatgrajai M, Merle A, Mukherji N, Quade A. The Problem of Substandard Medicines in Developing Countries. 2012. Available from: https://lafollette.wisc.edu/images/publications/workshops/2012-medicines.pdf: p:81. (cited 2020 Apr 22).
   Google Scholar
• IRACM. Issue of the extent of fake drugs. 2013. [cited 2020 Jan 24]. Available from: https://www.iracm.com/en/fake-drugs/problematic/.
   Google Scholar
• Pisani E. How moves towards universal health coverage could encourage poor quality drugs: an essay by Elizabeth Pisani. BMJ. 2019;366:l5327.
   PubMedGoogle Scholar
• WHO. Tanzania is first African country to reach an important milestone in the regulation of medicines: WHO | Regional Office for Africa; 2018. [cited 2020 Feb 4]. Available from: https://www.afro.who.int/news/tanzania-first-african-country-reach-important-milestone-regulation-medicines.
   Google Scholar
• WHO. Policy: Evaluating and publicly designating regulatory authorities as WHO listed authorities: Draft for comments. 2020. [cited 2020 Feb 4]. Available from: https://www.who.int/medicines/areas/quality_safety/quality_assurance/QAS19_828_Policy_on_WHO_Listed_Authorities.pdf?ua=1.
   Google Scholar
• Beyeler N, Liu J, Sieverding M. A Systematic Review of the Role of Proprietary and Patent Medicine Vendors in Healthcare Provision in Nigeria. PLOS ONE. 2015;10(1):e0117165.
   PubMed Web of Science ®Google Scholar
• Buchner DL, Kitutu FE, Cross DE, Nakamoga E, Awor P. A cross-sectional study to identify the distribution and characteristics of licensed and unlicensed private drug shops in rural Eastern Uganda to inform an iCCM intervention to improve health outcomes for children under five years. PLOS ONE. 2019;14(1):e0209641.
   PubMed Web of Science ®Google Scholar
• Peters DH, Bloom G. Developing world: Bring order to unregulated health markets. Nature. 2012;487(7406):163–165.
   PubMed Web of Science ®Google Scholar
• Nigeria has low drugs manufacturing capacity - NAFDAC DG. Vanguard News. 2013 [cited 2020 Feb 4]. Available from: https://www.vanguardngr.com/2013/07/nigeria-has-low-drugs-manufacturing-capacity-nafdac-dg/.
   Google Scholar
• Pisani E, Nistor A-L, Hasnida A, Parmaksiz K, Xu J, Kok MO. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania. Wellcome Open Res. 2019;4:70.
   PubMedGoogle Scholar
• Zaman MH. Bitter Pills: The Global War on Counterfeit Drugs. 1st ed. New York: Oxford University Press; 2018. p. 280.
   Google Scholar
• Tauqeer F, Myhr K, Gopinathan U. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study. Health Policy Plan. 2019;34(6):440–449.
   PubMed Web of Science ®Google Scholar
• Khan B, Godman B, Babar A, Hussain S, Mahmood S, Aqeel T. Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for the future. GaBI J. 2016;5(4):156–163.
   Google Scholar
• WHO Prequalification of medicines. Medicines/Finished Pharmaceutical Products | WHO - Prequalification of Medicines Programme. 2020. [cited 2020 Feb 4]. Available from: https://extranet.who.int/prequal/content/prequalified-lists/medicines.
   Google Scholar
• Rousham EK, Islam MA, Nahar P, Lucas PJ, Naher N, Ahmed SM, et al. Pathways of antibiotic use in Bangladesh: qualitative protocol for the PAUSE study. BMJ Open. 2019;9(1):e028215.
   PubMed Web of Science ®Google Scholar
• Liu J, Prach LM, Treleaven E, Hansen M, Anyanti J, Jagha T, et al. The role of drug vendors in improving basic health-care services in Nigeria. Bull World Health Organ. 2016;94(4):267–275.
   PubMed Web of Science ®Google Scholar
• Medina E, Bel E, Suñé JM. Counterfeit medicines in Peru: a retrospective review (1997–2014). BMJ Open. 2016;6(4):e010387.
   PubMed Web of Science ®Google Scholar
• UNIDO. Pharmaceutical Sector Profile: Nigeria; 2011. p. 109. [cited 2020 Feb 4]. Available from: https://www.unido.org/sites/default/files/2011-04/Nigeria_Pharma%20Sector%20Profile_032011_Ebook_0.pdf.
   Google Scholar
• Yadav P. Health Product Supply Chains in Developing Countries: Diagnosis of the Root Causes of Underperformance and an Agenda for Reform. Health Syst Reform. 2015;1(2):142–154.
   PubMed Web of Science ®Google Scholar
• Pisa M, McCurdy D. Improving Global Health Supply Chains through Traceability. 2019. [cited 2020 Feb 4]. Available from: https://www.cgdev.org/publication/improving-global-health-supply-chains-through-traceability.
   Google Scholar
• Berendes S, Adeyemi O, Oladele EA, Oresanya OB, Okoh F, Valadez JJ. Are Patent Medicine Vendors Effective Agents in Malaria Control? Using Lot Quality Assurance Sampling to Assess Quality of Practice in Jigawa, Nigeria. PLOS ONE. 2012;7(9):e44775.
   PubMed Web of Science ®Google Scholar
• USP. Combating substandard and falsified medicines. 2017. [cited 2020 Jan 24]. Available from: https://www.usp.org/sites/default/files/usp/document/about/public-policy/combatting-substandard-and-falsified-medicines-policy-position.pdf.
   Google Scholar
• Aminu N, Sha’aban A, Abubakar A, Gwarzo MS. Unveiling the Peril of Substandard and Falsified Medicines to Public Health and Safety in Africa: Need for All-Out War to End the Menace. Med Access Point Care. 2017;1:maapoc.0000023.
   Google Scholar
• Lamy M, Liverani M. Tackling Substandard and Falsified Medicines in the Mekong: National Responses and Regional Prospects: Substandard Medicines in the Mekong. Asia Pac Policy Stud. 2015;2(2):245–254.
   Web of Science ®Google Scholar
• Hamilton WL, Doyle C, Halliwell-Ewen M, Lambert G. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies. Health Policy Plan. 2016;31(10):1448–1466.
   PubMed Web of Science ®Google Scholar
• Attaran A. Stopping Murder by Medicine: Introducing the Model Law on Medicine Crime. Am J Trop Med Hyg. 2015;92(6_Suppl):127–132.
   PubMed Web of Science ®Google Scholar
• Shaon AI. Fake drug factory busted in Dhaka: Dhaka Tribune; 2014. [cited 2020 Feb 4]. Available from: https://www.dhakatribune.com/uncategorized/2014/12/08/fake-drug-factory-busted-in-dhaka.
   Google Scholar
• Sylim P, Liu F, Marcelo A, Fontelo P. Blockchain Technology for Detecting Falsified and Substandard Drugs in Distribution: Pharmaceutical Supply Chain Intervention. JMIR Res Protoc. 2018;7(9):e10163.
   PubMed Web of Science ®Google Scholar
• Akinyandenu O. Counterfeit drugs in Nigeria: A threat to public health. Afr J Pharm Pharmacol. 2013;7(36):2571–2576.
   Google Scholar
• Akunyili D. Fake and counterfeit drugs in the health sector: The role of medical doctors. Ann Ibadan Postgrad Med. 2004;2(2):19–23.
   Google Scholar
• Webb S. A bitter pill to swallow: the problem of, and solutions to, Sub-Saharan Africa’s counterfeit pharmaceutical trade. J Glob Health. 2014; [cited 2020 Feb 4]; Available from: www.ghjournal.org/a-bitter-pill-to-swallow-the-problem-of-and-solutions-to-sub-saharan-africas-counterfeit-pharmaceutical-trade/.
   Google Scholar
• Jacobs TG, Robertson J, van den Ham HA, Iwamoto K, Bak Pedersen H, Mantel-Teeuwisse AK. Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review. BMC Health Serv Res. 2019;19(1):536.
   PubMed Web of Science ®Google Scholar
• Alrasheedy AA, Alsalloum MA, Almuqbil FA, Almuzaini MA, Aba Alkhayl BS, Albishri AS, et al. The impact of law enforcement on dispensing antibiotics without prescription: a multi-methods study from Saudi Arabia. Expert Rev Anti Infect Ther. 2020;18(1):87–97.
   PubMed Web of Science ®Google Scholar
• Cartwright R, Baric A. The rise of counterfeit pharmaceuticals in Africa. 16.
   Google Scholar
• Fadlallah R, El-Jardali F, Annan F, Azzam H, Akl EA. Strategies and Systems-Level Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review of Evidence Beyond Effectiveness. Pharm Med. 2016;30(5):263–276.
   PubMed Web of Science ®Google Scholar
• Nayyar GML, Attaran A, Clark JP, Culzoni MJ, Fernandez FM, Herrington JE, et al. Responding to the Pandemic of Falsified Medicines. Am J Trop Med Hyg. 2015;92(6_Suppl):113–118.
   PubMed Web of Science ®Google Scholar
• Roth L, Bempong D, Babigumira JB, Banoo S, Cooke E, Jeffreys D, et al. Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. Glob Health. 2018;14(1):102.
   PubMedGoogle Scholar
• Vickers S, Bernier M, Zambrzycki S, Fernandez FM, Newton PN, Caillet C. Field detection devices for screening the quality of medicines: a systematic review. BMJ Glob Health. 2018;3(4):e000725.
   PubMed Web of Science ®Google Scholar
• Roth S, Ball D, Khetrapal S. Portable Screening Devices for Medicine Quality: Putting Power into the Hands of Regulators in Low-Resource Settings. 2018. [cited 2020 Feb 4]; Available from: https://think-asia.org/handle/11540/8800.
   Google Scholar
• Vorrath J, Voss M. The Hidden Dangers of Falsified and Substandard Medicines. Developing Countries Are Most Affected by the Illegal Trade; 2019. p. 4. Available from: https://www.swp-berlin.org/fileadmin/contents/products/comments/2019C25_vrr_vos.pdf. (cited 2020 Apr 22).
   Google Scholar
• Fadlallah R, El-Jardali F, Hemadi N, Morsi RZ, Abou Samra CA, Ahmad A, et al. Barriers and facilitators to implementation, uptake and sustainability of community-based health insurance schemes in low- and middle-income countries: a systematic review. Int J Equity Health. 2018;17(1):13.
   PubMedGoogle Scholar
• Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence. Health Policy. 2011;100(2):134–143.
   PubMed Web of Science ®Google Scholar
• Wagner AK, Graves AJ, Reiss SK, Lecates R, Zhang F, Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. Health Policy. 2011;100(2–3):151–158.
   PubMed Web of Science ®Google Scholar
• Dalinjong PA, Welaga P, Akazili J, Kwarteng A, Bangha M, Oduro A, et al. The association between health insurance status and utilization of health services in rural Northern Ghana: evidence from the introduction of the National Health Insurance Scheme. J Health Popul Nutr. 2017;36(1):42.
   PubMedGoogle Scholar
• Gnawali DP, Pokhrel S, Sié A, Sanon M, De Allegri M, Souares A, et al. The effect of community-based health insurance on the utilization of modern health care services: Evidence from Burkina Faso. Health Policy. 2009;90(2–3):214–222.
   PubMed Web of Science ®Google Scholar
• Spaan E, Mathijssen J, Tromp N, McBain F, ten Have A, Baltussen R. The impact of health insurance in Africa and Asia: a systematic review. Bull World Health Org. 2012;90(9):685–692.
   PubMed Web of Science ®Google Scholar
• Rutta E, Liana J, Embrey M, et al. Accrediting retail drug shops to strengthen Tanzania’s public health system: an ADDO case study [published correction appears in J Pharm Policy Pract. 2015;8:29]. J Pharm Policy Pract. 2015;8:23. Published 2015 Sep 25. https://doi.org/10.1186/s40545-015-0044-4.
   PubMedGoogle Scholar
• Correspondent S, bdnews24.com. Bangladesh to introduce ‘model pharmacy’ to stop fake drug sales. 2016 [cited 2020 Feb 4]. Available from: https://bdnews24.com/health/2016/08/10/bangladesh-to-introduce-model-pharmacy-to-stop-fake-drug-sales.
   Google Scholar
• Embrey M, Vialle-Valentin C, Dillip A, Kihiyo B, Mbwasi R, Semali IA, et al. Understanding the Role of Accredited Drug Dispensing Outlets in Tanzania’s Health System. Marsh V, editor. PLoS ONE. 2016;11(11):e0164332.
   PubMed Web of Science ®Google Scholar
• Mwita S, Jande M, Marwa K, Hamasaki K, Katabalo D, Burger J, et al. Medicines dispensers’ knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. J Pharm Health Serv Res. 2017;8(4):227–233.
   Google Scholar
• Mukokinya MA, Opanga S, Oluka M, Godman B. Dispensing of antimicrobials in Kenya: A cross-sectional pilot study and its implications. J Res Pharm Pract. 2018;7(2):77.
   PubMed Web of Science ®Google Scholar
• Ibrahim A, NAFDAC. Pharmacovigilance-Newsletter_Vol-9.pdf. 2016. [cited 2020 Feb 4]. Available from: https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Pharmacovigilance_Newsletter/Pharmacovigilance-Newsletter_Vol-9.pdf.
   Google Scholar
• Binagwaho A, Bate R, Gasana M, Karema C, Mucyo Y, Mwesigye JP, et al. Combatting substandard and falsified medicines: a view from Rwanda. PLoS Med. 2013;10(7):e1001476.
   PubMed Web of Science ®Google Scholar
• Silverman R, Keller JM, Glassman A, Chalkidou K. Tackling the Triple Transition in Global Health Procurement. 2019. [cited 2020 Feb 4]. Available from: https://www.cgdev.org/better-health-procurement.
   Google Scholar
• ABPI: The Association of the British Pharmaceutical Industry. Falsified Medicines Directive (FMD) | ABPI. 2020. [cited 2020 Feb 4]. Available from: https://www.abpi.org.uk/new-medicines/supply-chain/falsified-medicines-directive-fmd/.
   Google Scholar
• Robinson J, Editor S. Falsified Medicines Directive (FMD): how it will work. Pharma J. 2018. [cited 2020 Feb 4]. Available from: https://www.pharmaceutical-journal.com/news-and-analysis/infographics/falsified-medicines-directive-fmd-how-it-will-work/20204433.article.
   Google Scholar
• Barojas A. The Three-Level Approach: A Framework for Ensuring Medicines Quality in Limited-Resource Countries. Pharmaceut Reg Affairs. 2014;03(01) [cited 2019 Oct 4]; Available from: http://www.omicsgroup.org/journals/the-threelevel-approach-a-framework-for-ensuring-medicines-quality-in-limitedresource-countries-2167-7689.1000117.php?aid=24068.
   Google Scholar
• WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Expert Committee on Specifications for Pharmaceutical Preparations: fiftieth report. Geneva: WHO; 2016. p. 358. (WHO technical report series).
   Google Scholar
• Ecumenical Pharmaceutical Network. Assuring the Quality of Medicines. [cited 2020 Feb 4]. Available from: https://apps.who.int/medicinedocs/fr/m/abstract/Js19964en/.
   Google Scholar
• Petersen A, Held N, Heide L, Group on behalf of the D-EMS. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab. PLOS ONE. 2017;12(9):e0184165.
   PubMed Web of Science ®Google Scholar
• Kusumewera D. Health Action International: Mission-Sector. [cited 2020 Feb 4]. Available from: https://haiweb.org/wp-content/uploads/2019/12/Mission-Sector.pdf.
   Google Scholar
• Rasheed H, Höllein L, Holzgrabe U. Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries. Front Pharmacol. 2018;9:995.
   PubMed Web of Science ®Google Scholar
• Makgetla I. Oral history program: Governance Traps, Interview no H1. 20098.
   Google Scholar
• Emmen MB. Crowdsourcing the Fight Against Fake Drugs: GAB | The Global Anticorruption Blog; 2014. [cited 2020 Feb 4]. Available from: https://globalanticorruptionblog.com/2014/12/12/crowdsourcing-the-fight-against-fake-drugs/.
   Google Scholar
• WHO. WHO welcomes landmark UN declaration on universal health coverage. 2020. Available from: https://www.who.int/news-room/detail/23-09-2019-who-welcomes-landmark-un-declaration-on-universal-health-coverage. Accessed 22 Apr 2020.
   Google Scholar